{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:57:55Z","timestamp":1783018675317,"version":"3.54.6"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T00:00:00Z","timestamp":1496880000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s00259-017-3704-6","type":"journal-article","created":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T05:37:43Z","timestamp":1496900263000},"page":"1559-1574","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Highlights lecture EANM 2016: \u201cEmbracing molecular imaging and multi-modal imaging: a smart move for nuclear medicine towards personalized medicine\u201d"],"prefix":"10.1007","volume":"44","author":[{"given":"Eric O.","family":"Aboagye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Kraeber-Bod\u00e9r\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,8]]},"reference":[{"key":"3704_CR1","doi-asserted-by":"crossref","first-page":"74362","DOI":"10.18632\/oncotarget.11413","volume":"7","author":"P Bossi","year":"2016","unstructured":"Bossi P, Resteghini C, Paielli N, Licitra L, Pilotti S, Perrone F. Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma. Oncotarget. 2016;7:74362\u201379.","journal-title":"Oncotarget"},{"key":"3704_CR2","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1007\/s13277-013-1303-0","volume":"35","author":"S Keren","year":"2014","unstructured":"Keren S, Shoude Z, Lu Z, Beibei Y. Role of EGFR as a prognostic factor for survival in head and neck cancer: a meta-analysis. Tumour Biol. 2014;35:2285\u201395.","journal-title":"Tumour Biol"},{"issue":"Suppl 1","key":"3704_CR3","first-page":"S231","volume":"43","author":"TA Burley","year":"2016","unstructured":"Burley TA, Martins CD, Da Pieve C, Allott L, Smith R, Ciobota DM, et al. Imaging EGFR in head and neck cancer: useful prognostic and treatment monitoring tool? Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S231.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3704_CR4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrd4591","volume":"14","author":"KM Mahoney","year":"2015","unstructured":"Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14:561\u201384.","journal-title":"Nat Rev Drug Discov"},{"issue":"Suppl 1","key":"3704_CR5","first-page":"S147","volume":"43","author":"S Heskamp","year":"2016","unstructured":"Heskamp S, Molkenboer-Kuenen JDM, van de Vondervoort RHAM, Boerman OC. SPECT\/CT imaging of the PD-1\/PD-L1 immune checkpoint pathway in syngeneic murine tumor models. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S147.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR6","first-page":"S146","volume":"43","author":"CS Miranda","year":"2016","unstructured":"Miranda CS, Burke BP, Lee RE, Nigam S, Clemente G, Thompson JA, et al. CXCR4 chemokine receptor imaging: evaluation and validation of a new configurationally restricted tetraazamacrocyclic CXCR4 antagonist, 64Cu-CB-bicyclam. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S146.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3704_CR7","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2967\/jnumed.115.161034","volume":"57","author":"T Vag","year":"2016","unstructured":"Vag T, Gerngross C, Herhaus P, Eiber M, Philipp-Abbrederis K, Graner FP, et al. First experience with chemokine receptor CXCR4-targeted PET imaging of patients with solid cancers. J Nucl Med. 2016;57:741\u20136.","journal-title":"J Nucl Med"},{"issue":"Suppl 1","key":"3704_CR8","first-page":"S125","volume":"43","author":"A Leisser","year":"2016","unstructured":"Leisser A, Raderer M, Mayerh\u00f6fer M, Wadsak W, Mitterhauser M, Hartenbach M, et al. Prospective non-invasive evaluation of CXCR4 expression for diagnosis of MALT lymphoma using 68Ga-pentixafor PET\/MRI \u2013 initial experience. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S125.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR9","first-page":"S39","volume":"43","author":"M Hekman","year":"2016","unstructured":"Hekman M, Rijpkema M, Mulders P, Oosterwijk E, Boerman O, Oyen WJG. Zirconium-89-girentuximab PET\/CT imaging in renal cell carcinoma: first in man results. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S39.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR10","first-page":"28","volume":"43","author":"A Iagaru","year":"2016","unstructured":"Iagaru A, Sonni I, Minamimoto R, Loening A, Vasanawala S. Ga68 RM2 PET\/MRI evaluation of gastrin-releasing peptide receptor status in patients with biochemically recurrent prostate cancer and negative conventional imaging. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):28.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3704_CR11","doi-asserted-by":"crossref","first-page":"12787","DOI":"10.1523\/JNEUROSCI.3657-09.2009","volume":"29","author":"R Vassar","year":"2009","unstructured":"Vassar R, Kovacs DM, Yan R, Wong PC. The beta-secretase enzyme BACE in health and Alzheimer\u2019s disease: regulation, cell biology, function, and therapeutic potential. J Neurosci. 2009;29:12787\u201394.","journal-title":"J Neurosci"},{"key":"3704_CR12","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1002\/glia.22986","volume":"64","author":"DD Pearse","year":"2016","unstructured":"Pearse DD, Hughes ZA. PDE4B as a microglia target to reduce neuroinflammation. Glia. 2016;64:1698\u2013709.","journal-title":"Glia"},{"key":"3704_CR13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrn3406","volume":"14","author":"HA Lashuel","year":"2013","unstructured":"Lashuel HA, Overk CR, Oueslati A, Masliah E. The many faces of \u03b1-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci. 2013;14:38\u201348.","journal-title":"Nat Rev Neurosci"},{"issue":"Suppl 1","key":"3704_CR14","first-page":"S94","volume":"43","author":"A Takano","year":"2016","unstructured":"Takano A, Chen L, Nag S, Brodney MA, Amini N, Chang C, et al. Radio-labeling and initial evaluation of a novel beta-secretase (BACE)-selective PET radioligand, [18F]PF-06684511, in nonhuman primates. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S94.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR15","first-page":"S97","volume":"43","author":"L Chen","year":"2016","unstructured":"Chen L, Zasadny K, Beck EM, Chang C, Chappie T, Coelho RV, et al. In vivo evaluation of [18F]PF-06445974, a novel phosphodiesterase 4D sparing PET radioligand for the phosphodiesterase 4 enzyme, in nonhuman primates. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S97.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR16","first-page":"S22","volume":"43","author":"B Hooshyar Yousefi","year":"2016","unstructured":"Hooshyar Yousefi B, Mohring M, Arzberger T, H\u00f6glinger G, Wester H, Schwaiger M. Novel compounds for specific visualization of \u03b1-synucleinopathies by PET. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S22.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR17","first-page":"S536","volume":"43","author":"H Strauss","year":"2016","unstructured":"Strauss H, Gheysens O, Hustinx R, Goldman S, Eissler K, Lyons E, et al. Safety analysis of a novel fatty acid analog 18-F FCPHA, data from a phase II study. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S536.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR18","first-page":"S131","volume":"43","author":"Z Varasteh","year":"2016","unstructured":"Varasteh Z, Hyafil F, Diallo D, Aid R, Anizan N, Mohring M, Vigne J, et al. Targeting mannose receptor (MR) expressed on macrophages for imaging of atherosclerosis in a murine model using tilmanocept. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S131.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3704_CR19","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/anie.201611207","volume":"56","author":"G Nagy","year":"2017","unstructured":"Nagy G, Szikra D, Trencs\u00e9nyi G, Fekete A, Garai I, Giani AM, et al. AAZTA: an ideal chelating agent for the development of 44Sc PET imaging agents. Angew Chem Int Ed Engl. 2017;56:2118\u201322.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"1","key":"3704_CR20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40658-015-0136-x","volume":"2","author":"R Walczak","year":"2015","unstructured":"Walczak R, Krajewski S, Szkliniarz K, Sitarz M, Abbas K, Choi\u0144ski J, et al. Cyclotron production of (43)Sc for PET imaging. EJNMMI Phys. 2015;2(1):33.","journal-title":"EJNMMI Phys"},{"issue":"Suppl 1","key":"3704_CR21","first-page":"S200","volume":"43","author":"M Sitarz","year":"2016","unstructured":"Sitarz M, Szkliniarz K, Walczak R, Jastrz\u0119bski J, Choi\u0144ski J, Majkowska A, et al. Production yield and isotopic purity of medical Sc radioisotopes formed by proton, deuteron and alpha particle beams. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S200.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3704_CR22","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.acra.2015.09.008","volume":"23","author":"TJ Fraum","year":"2016","unstructured":"Fraum TJ, Fowler KJ, McConathy J. PET\/MRI: emerging clinical applications in oncology. Acad Radiol. 2016;23:220\u201336.","journal-title":"Acad Radiol"},{"issue":"Suppl 1","key":"3704_CR23","first-page":"S195","volume":"43","author":"M Grech-Sollars","year":"2016","unstructured":"Grech-Sollars M, Ordidge KL, Vaqas B, Honeyfield L, Khan S, Camp S, et al. 18F-fluoromethylcholine (FMC) PET\/CT and proton magnetic resonance spectroscopy; imaging and tissue biomarkers of cell membrane turnover in primary brain gliomas \u2013 a pilot study. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S195.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3704_CR24","doi-asserted-by":"crossref","first-page":"8047","DOI":"10.1088\/0031-9155\/60\/20\/8047","volume":"60","author":"CN Ladefoged","year":"2015","unstructured":"Ladefoged CN, Benoit D, Law I, Holm S, Kj\u00e6r A, H\u00f8jgaard L, et al. Region specific optimization of continuous linear attenuation coefficients based on UTE (RESOLUTE): application to PET\/MR brain imaging. Phys Med Biol. 2015;60:8047\u201365.","journal-title":"Phys Med Biol"},{"issue":"Suppl 1","key":"3704_CR25","first-page":"S177","volume":"43","author":"CN Ladefoged","year":"2016","unstructured":"Ladefoged CN, Law I, Hassing C, H\u00f8jgaard L, Andersen FL. The use of RESOLUTE brain attenuation correction in [18F]-fluoroethyl- tyrosine (18F-FET) PET\/MRI of gliomas. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S177.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR26","first-page":"S152","volume":"43","author":"I Sonni","year":"2016","unstructured":"Sonni I, Minamimoto R, Taviani V, Loening A, Gambhir SS, Vasanawala S, et al. Imaging patients with breast and prostate cancers using combined 18F-NaF\/18F-FDG and TOF simultaneous PET\/MRI. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S152.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR27","first-page":"S165","volume":"43","author":"M Hartenbach","year":"2016","unstructured":"Hartenbach M, Baltzer P, Hartenbach S, Susani M, Seitz C, Kenner L, et al. Staging primary prostate cancer with 68Ga-PSMAHBED-CC\/[18F]fluorocholine-PET\/MRI. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S165.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR28","first-page":"S61","volume":"43","author":"R Abgral","year":"2016","unstructured":"Abgral R, Dweck MR, Trivieri MG, Robson PM, Karakatsanis N, Mani V, et al. Usefulness of combined FDG-PET\/MR to diagnose active cardiac sarcoidosis. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S61.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3704_CR29","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.nucmedbio.2016.08.006","volume":"43","author":"MR Pillai","year":"2016","unstructured":"Pillai MR, Nanabala R, Joy A, Sasikumar A, Russ Knapp FF. Radiolabeled enzyme inhibitors and binding agents targeting PSMA: effective theranostic tools for imaging and therapy of prostate cancer. Nucl Med Biol. 2016;43:692\u2013720.","journal-title":"Nucl Med Biol"},{"key":"3704_CR30","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s00259-016-3572-5","volume":"44","author":"C Berliner","year":"2017","unstructured":"Berliner C, Tienken M, Frenzel T, Kobayashi Y, Helberg A, Kirchner U, et al. Detection rate of PET\/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC. Eur J Nucl Med Mol Imaging. 2017;44:670\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3704_CR31","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.184457","author":"I Einspieler","year":"2017","unstructured":"Einspieler I, Rauscher I, D\u00fcwel C, Kr\u00f6nke M, Rischpler C, Habl G, et al. Detection efficacy of hybrid 68Ga-PSMA ligand PET\/CT in prostate cancer patients with biochemical recurrence after primary radiation therapy defined by Phoenix criteria. J Nucl Med. 2017. doi: 10.2967\/jnumed.116.184457 .","journal-title":"J Nucl Med"},{"key":"3704_CR32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00259-015-3174-7","volume":"43","author":"A Delker","year":"2016","unstructured":"Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, et al. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:42\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3704_CR33","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.juro.2016.02.2969","volume":"196","author":"MM Heck","year":"2016","unstructured":"Heck MM, Retz M, D\u2019Alessandria C, Rauscher I, Scheidhauer K, Maurer T, et al. Systemic radioligand therapy with (177)Lu labeled prostate specific membrane antigen ligand for imaging and therapy in patients with metastatic castration resistant prostate cancer. J Urol. 2016;196:382\u201391.","journal-title":"J Urol"},{"key":"3704_CR34","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, et al. 225Ac-PSMA-617 for PSMA-targeted \u03b1-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941\u20134.","journal-title":"J Nucl Med"},{"key":"3704_CR35","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.2967\/jnumed.116.174300","volume":"57","author":"AP Kiess","year":"2016","unstructured":"Kiess AP, Minn I, Vaidyanathan G, Hobbs RF, Josefsson A, Shen C, et al. (2S)-2-(3-(1-Carboxy-5-(4-211At-astatobenzamido)pentyl)ureido)-pentanedioic acid for PSMA-targeted \u03b1-particle radiopharmaceutical therapy. J Nucl Med. 2016;57:1569\u201375.","journal-title":"J Nucl Med"},{"issue":"Suppl 1","key":"3704_CR36","first-page":"S28","volume":"43","author":"F Ceci","year":"2016","unstructured":"Ceci F, Castellucci P, Graziani T, Fonti C, Lodi F, Boschi S, et al. 68Ga-PSMA PET\/CT for early restaging prostate cancer. Preliminary results of a prospective trial in patients with biochemical failure after radical therapy and PSA levels <2 ng\/mL. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S28.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR37","first-page":"S35","volume":"43","author":"JB Nielsen","year":"2016","unstructured":"Nielsen JB, Zacho HD, Dettmann K, Landkilde NC, Jensen JB, Haberkorn U, et al. Detection rates of 68Ga-PSMA PET\/CT in patients with biochemical relapse from prostate cancer after radical prostatectomy and PSA values <1 ng\/ml: preliminary results from a prospective, multicenter trial. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S35.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR38","first-page":"S138","volume":"43","author":"C Uprimny","year":"2016","unstructured":"Uprimny C, Kroiss A, Decristoforo C, Scarpa L, Kendler D, Geraldo L, et al. Validation of 68Ga-PSMA-ligand-PET\/CT in primary staging of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR39","first-page":"S167","volume":"43","author":"C Schiller","year":"2016","unstructured":"Schiller C, Beheshti M, Geinitz H, Aschacher B, Moinfar F, Broinger G, et al. 68Ga-PSMA PET\/CT in preoperative staging of intermediate and high risk prostate cancer patients. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S167.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR40","first-page":"S344","volume":"43","author":"V Gangemi","year":"2016","unstructured":"Gangemi V, Damiano R, Calabria F, Barbato F, Cascini GL. Preliminary experience with Cu64PSMA PETCT in patients with intermediate and high risk prostate cancer (PC) before prostatectomy. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S344.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR41","first-page":"S212","volume":"43","author":"J Ferdinandus","year":"2016","unstructured":"Ferdinandus J, Eppard E, K\u00fcrpig S, G\u00e4rtner F, Fimmers R, Yordanova A, et al. Predictors of better response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S212.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR42","first-page":"S235","volume":"43","author":"Z Khurshid","year":"2016","unstructured":"Khurshid Z, Ahmadzadehfar H, Gaertner F, Papp L, Zs\u00f3t\u00e9r N, Essler M, et al. Pre-(177Lu-PSMA) therapy response prediction by textural heterogeneity parameters in 68Ga-PSMA PET scans among patients with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S235.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR43","first-page":"S37","volume":"43","author":"HR Kulkarni","year":"2016","unstructured":"Kulkarni HR, Singh A, Baum RP. Differential response of bone versus lymph node metastases after Lu-177 labelled PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S37.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR44","first-page":"S36","volume":"43","author":"P Kletting","year":"2016","unstructured":"Kletting P, Hardiansyah D, Beer AJ, Glatting G. Protection of normal tissue in molecular radiotherapy with 177Lu-labeled PSMA-targeting peptides using preloading. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S36.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR45","first-page":"S121","volume":"43","author":"J Strosberg","year":"2016","unstructured":"Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, et al. NETTER-1 phase III in patients with midgut neuroendocrine tumours treated with 177Lu-Dotatate: efficacy and safety results. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S121.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR46","first-page":"S158","volume":"43","author":"AJB McEwan","year":"2016","unstructured":"McEwan AJB, Wieler M, Sawyer MB, Morrish DW, Schaitel BA, Schrader LD, et al. Induction and maintenance regimen with peptide receptor radionuclide therapy: Lu-177-DOTA-TATE (PRRT) improves progression free survival (PFS) in patients with advanced neuroendocrine tumours (NETs). Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S158.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR47","first-page":"S121","volume":"43","author":"J Kunikowska","year":"2016","unstructured":"Kunikowska J, Pawlak D, Bak M, Kos-Kudla B, Mikolajczak R, Krolicki L. Tandem peptide radionuclide therapy with 90Y\/177Lu-DOTATATE clinical results and long term side effect \u2013 10 years\u2019 experience. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S121.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR48","first-page":"S224","volume":"43","author":"A Filice","year":"2016","unstructured":"Filice A, Fioroni F, Grassi E, Tartaglione A, Fraternali A, Asti M, et al. Can PET\/CT 68Ga-DOTA-peptides uptake predict the absorbed dose in peptide receptor radionuclide therapy (PRRT)? Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S224.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR49","first-page":"S50","volume":"43","author":"G Nicolas","year":"2016","unstructured":"Nicolas G, Schreiter N, Kaul F, Uiters J, Mena R, Bauman A, Kaufmann J, et al. Comparison between the antagonist 68Ga-OPS202 and the agonist 68Ga-DOTATOC for somatostatin receptor PET\/CT in gastroenteropancreatic NET patients: results of a phase 1\/2 study. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S50.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR50","first-page":"S105","volume":"43","author":"SR Dubash","year":"2016","unstructured":"Dubash SR, Keat N, Mapelli P, Twyman F, Carroll L, Kozlowski K, et al. Biodistribution, radiation dosimetry and first preliminary results of a novel 18F-fluoroethyl triazole [Tyr3] octreotate analogue for PET imaging in locally advanced and metastatic neuroendocrine tumour patients. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S105.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3704_CR51","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","volume":"32","author":"SF Barrington","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, M\u00fceller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048\u201358.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"3704_CR52","first-page":"S125","volume":"43","author":"S Kanoun","year":"2016","unstructured":"Kanoun S, Berriolo-Riedinger A, Tal I, Edeline V, Cottereau A, Brice P, et al. Prognosis value of baseline total metabolic tumor volume (TMTV) in advanced Hodgkin lymphoma (HL): ancillary study of AHL2011 LYSA trial. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S125.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR53","first-page":"S202","volume":"43","author":"C Bailly","year":"2016","unstructured":"Bailly C, Carlier T, Meignan M, Gallazzini Crepin C, Beriollo Riedinger A, Devillers A, et al. Prognosis value of FDG-PET parameters at diagnosis and after induction in patients with mantle cell lymphoma, interim results from the LyMa-PET project, a LYSA study. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S202.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR54","first-page":"S274","volume":"43","author":"M Martinez de Bourio","year":"2016","unstructured":"Martinez de Bourio M, Jimenez-Ballv\u00e9 A, Salsidua Arroyo O, Serrano-Palacio A, Ortega-Candil A, Rodriguez-Rey C, et al. Locally advanced breast cancer: utility of volumetric parameters in 18F-FDG PET\/CT scans to predict recurrence and overall survival. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S274.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR55","first-page":"S270","volume":"43","author":"S Boughdad","year":"2016","unstructured":"Boughdad S, Nioche C, Orlhac F, Champion L, Alberini J, Buvat I. Variations of FDG PET\/CT SUV and textural indices in breast cancer according to metastatic status. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S270.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR56","first-page":"S75","volume":"43","author":"L Antunovic","year":"2016","unstructured":"Antunovic L, Gallivanone F, Sagona A, Manfrinato G, Sollini M, Kirienko M, et al. Advanced 18F-FDG PET\/CT imaging analysis in selected series of breast cancer patients. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S75.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR57","first-page":"S156","volume":"43","author":"C Nioche","year":"2016","unstructured":"Nioche C, Orlhac F, Soussan M, Boughdad S, Alberini J, Buvat I. A software for characterizing intra-tumor heterogeneity in multimodality imaging and establishing reference charts. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S156.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR58","first-page":"S195","volume":"43","author":"A Chiaravalloti","year":"2016","unstructured":"Chiaravalloti A, Fiorentini A, Villani V, Carapella C, D\u2019Elia A, Sannino P, et al. Overall survival and progression free survival in patients with primary brain tumors after treatment. Is 18F FDOPA PET\/CT a prognostic factor in these patients? Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S195.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR59","first-page":"S260","volume":"43","author":"T Skvortsova","year":"2016","unstructured":"Skvortsova T, Savintseva Z, Zakhs D, Medvedev S, Bechtereva NP. Diagnostic value of PET using [11C]methionine in suspected glioma recurrence. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S260.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR60","first-page":"S196","volume":"43","author":"E Lopci","year":"2016","unstructured":"Lopci E, Riva M, Olivari L, Raneri F, Bizzi A, Fernandes B, et al. Prognostic significance of molecular and imaging biomarkers in primary brain tumors. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S196.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR61","first-page":"S75","volume":"43","author":"L Papp","year":"2016","unstructured":"Papp L, Nakuz TS, Magometschnigg HF, Pinker K, Haug A, Helbich TH, et al. Breast cancer grading of 18F-FDG-PET\/CT and patient-derived statistical features based on supervised machine-learning approaches. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S75.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR62","first-page":"S150","volume":"43","author":"L Papp","year":"2016","unstructured":"Papp L, Hartenbach S, Duhovic A, Baltzer P, Rausch I, Beyer T, et al. Evaluation of primary prostate pathologies by large-scale analysis of non-invasive PET-MRI features with machine-learning approaches. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S150.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR63","first-page":"S193","volume":"43","author":"L Papp","year":"2016","unstructured":"Papp L, P\u00f6tsch N, Mitterhauser M, Wadsak W, Beyer T, Hacker M, et al. Automated grading of glioma based on MET-PET and patient-derived features utilizing multi-layer machine learning approaches. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S193.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR64","first-page":"S127","volume":"43","author":"B Garcia","year":"2016","unstructured":"Garcia B, Morales M, Guillen EF, Figueroa R, Marcos M, Moran V, et al. 11C-methionine PET\/CT in multiple myeloma: comparison with 18FDG PET\/CT and diagnostic value through clinical and biological parameters. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S127.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR65","first-page":"S233","volume":"43","author":"L Zanoni","year":"2016","unstructured":"Zanoni L, Broccoli A, Lambertini A, Pellegrini C, Stefoni V, Lodi F, et al. The role of 18F-fluorothymidine (18F-FLT) in patients with suspected lymphoma relapse. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S233.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3704_CR66","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Foss\u00e5 SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213\u201323.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"3704_CR67","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1007\/s13139-016-0414-0","volume":"43","author":"HH Lee","year":"2016","unstructured":"Lee HH, McAddy NC, O\u2019Sullivan P, Crawley P, Beesley S, Naji M. Radium-223 dichloride treatment for prostate cancer with bone metastases: a symptomatic outcome review of 12 months experience. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S102.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR68","first-page":"S214","volume":"43","author":"GA Follacchio","year":"2016","unstructured":"Follacchio GA, Frantellizzi V, Liberatore M, Monteleone F, DeVincentis G. Pain response and acute hematologic toxicity in castration-resistant prostate cancer (CRPC) patients (pts) treated with 223Ra-dichloride: a single-center clinical series. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S214.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3704_CR69","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40658-016-0153-4","volume":"3","author":"J Svensson","year":"2016","unstructured":"Svensson J, Hagmarker L, Magnander T, W\u00e4ngberg B, Bernhardt P. Radiation exposure of the spleen during (177)Lu-DOTATATE treatment and its correlation with haematological toxicity and spleen volume. EJNMMI Phys. 2016;3:15.","journal-title":"EJNMMI Phys"},{"issue":"Suppl 1","key":"3704_CR70","first-page":"S159","volume":"43","author":"J Svensson","year":"2016","unstructured":"Svensson J, Hermann R, Holgersson K, W\u00e4ngberg B, Sundl\u00f6v A, Tennvall J, et al. Radiation exposure of the kidneys affects haematological response during 177Lu-DOTATATE treatment. Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S159.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"3704_CR71","first-page":"S189","volume":"43","author":"V Reijonen","year":"2016","unstructured":"Reijonen V, Heikkonen J, M\u00e4enp\u00e4\u00e4 H. Can the cumulative kidney dose be predicted on the basis of the first cycle in the standard Lu-177-octreotate treatment? Eur J Nucl Med Mol Imaging. 2016;43(Suppl 1):S189.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-017-3704-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-017-3704-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-017-3704-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T19:04:51Z","timestamp":1569438291000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-017-3704-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,8]]},"references-count":71,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["3704"],"URL":"https:\/\/doi.org\/10.1007\/s00259-017-3704-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,8]]}}}